Skip to content

Clinical application of remazolam in intervertebral foraminal endoscopy

Clinical application of remazolam in intervertebral foraminal endoscopy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055527
Enrollment
Unknown
Registered
2022-01-11
Start date
2022-01-11
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation

Interventions

Experiment Group:Remazolam

Sponsors

The First Affiliated Hospital of Gannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, BMI: 18 to 27; 2. ASA class I-II; 3. Volunteered to participate in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Contraindications to the drugs used in this study; 2. Patients with airway difficulty: the modified maiiampati score was grade III or IV; 3. Bradycardia and various conduction block of intracardiac conduction system; 4. With cognitive impairment, mental history and history of psychotropic substance abuse before operation; 5. Acute stage of respiratory diseases, complicated with heart disease, endocrine system diseases, abnormal liver and kidney function; 6. Patients with abnormal coagulation function, myasthenia gravis and severe depression

Design outcomes

Primary

MeasureTime frame
Hemodynamics;Degree of sedation;Incidence of adverse reactions;

Secondary

MeasureTime frame
Stress index;Intraoperative agitation;Local anesthetic dosage;Vasoactive drug dosage;Postoperative nausea and vomiting;Doctor and patient satisfaction;Operation time;Operation time;

Countries

China

Contacts

Public ContactHuang Kenv

The First Affiliated Hospital of Gannan Medical College

2246852190@qq.com+86 15770726381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026